Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoroquinolones in paediatrics.

D Gendrel1, F Moulin

  • 1Department of Paediatrics, Hĵpital Saint Vincent de Paul, Paris, France. dominique.gendrel@svp.ap-hop-paris.fr

Paediatric Drugs
|June 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of heparin-induced HGF release in the acute phase of STEMI.

Frontiers in cardiovascular medicine·2025
Same author

Severe atypical Lemierre syndrome caused by methicillin-sensitive Staphylococcus aureus: Two pediatric case reports.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2023
Same author

Two pediatric cases of multisystem inflammatory-like syndrome following COVID-19 vaccination.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

Infant botulism: Report of a misleading case and important key messages.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

Severe and fatal forms of COVID-19 in children.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2020
Same author

The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations.

The British journal of dermatology·2020
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Fluoroquinolones are effective antibiotics but have limited pediatric use due to joint toxicity concerns. However, ciprofloxacin shows similar safety in children and adults, suggesting potential for specific pediatric infections.

Area of Science:

  • Pharmacology and Therapeutics
  • Pediatric Infectious Diseases
  • Microbiology

Background:

  • Fluoroquinolones are broad-spectrum bactericidal antibiotics with excellent tissue penetration, widely used in adults.
  • Concerns regarding potential joint toxicity in pediatric patients have historically limited their use in children.
  • Evolving pathogen resistance patterns highlight the need to re-evaluate antibiotic options, including fluoroquinolones.

Purpose of the Study:

  • To review the potential indications and safety profile of fluoroquinolones in pediatric populations.
  • To assess the risk of arthrotoxicity in children compared to adults.
  • To discuss the evolving role of fluoroquinolones in treating resistant infections in children.

Main Methods:

  • Review of existing clinical data and experimental findings on fluoroquinolone use and toxicity in pediatric patients.

Related Experiment Videos

  • Analysis of pathogen susceptibility trends to fluoroquinolones.
  • Comparison of arthrotoxicity incidence between pediatric and adult populations treated with ciprofloxacin.

    • Main Results:

    • Fluoroquinolones demonstrate activity against various pediatric pathogens, including resistant Salmonella, Shigella, and Enterobacteriaceae.
    • Available data suggests ciprofloxacin's arthrotoxicity incidence in children is comparable to that in adults.
    • Third-generation fluoroquinolones show improved Gram-positive activity, with potential applications in respiratory and ENT infections.

    Conclusions:

    • Fluoroquinolones represent a valuable second-line option for specific, severe pediatric infections, particularly those with resistant pathogens.
    • Routine use in children remains limited due to potential joint complications and alternative treatments, but ciprofloxacin appears safe.
    • Future fluoroquinolones may find indications in conditions like pneumococcal meningitis, pending further safety and efficacy data.